Dr. Mark Hyman

And lo and behold, in these individuals, when they consumed that level of these polyphenols over the course of 90 days, so three months, what did we find? Now, we were told when we started this study, we probably wouldn't find anything of statistical significance because the background of diet would overcome whatever signal we're getting from the supplement.

And lo and behold, in these individuals, when they consumed that level of these polyphenols over the course of 90 days, so three months, what did we find? Now, we were told when we started this study, we probably wouldn't find anything of statistical significance because the background of diet would overcome whatever signal we're getting from the supplement.

But it turns out that was wrong, that the signal was so strong on our immune system of these 50 subjects that we had in the trial that some of the epigenetic patterns in their immune genes were amplified or altered by 20-fold. Wow. Not 20%, 20-fold. I mean, it just stood out like the Empire State Building off of the other gene array. That's like 2,000%. Right, exactly.

But it turns out that was wrong, that the signal was so strong on our immune system of these 50 subjects that we had in the trial that some of the epigenetic patterns in their immune genes were amplified or altered by 20-fold. Wow. Not 20%, 20-fold. I mean, it just stood out like the Empire State Building off of the other gene array. That's like 2,000%. Right, exactly.

But it turns out that was wrong, that the signal was so strong on our immune system of these 50 subjects that we had in the trial that some of the epigenetic patterns in their immune genes were amplified or altered by 20-fold. Wow. Not 20%, 20-fold. I mean, it just stood out like the Empire State Building off of the other gene array. That's like 2,000%. Right, exactly.

So then people would say, okay, interesting, but does it mean anything? So then we did a functional analysis as to what were these genes regulating in terms of the cell function. And they were regulating two interesting pathways or networks. One is called the ceramide kinase network, and the other is called COP9.

So then people would say, okay, interesting, but does it mean anything? So then we did a functional analysis as to what were these genes regulating in terms of the cell function. And they were regulating two interesting pathways or networks. One is called the ceramide kinase network, and the other is called COP9.

So then people would say, okay, interesting, but does it mean anything? So then we did a functional analysis as to what were these genes regulating in terms of the cell function. And they were regulating two interesting pathways or networks. One is called the ceramide kinase network, and the other is called COP9.

This is a little scientific geekism, but what I'll tell you is that both of those are fundamental longevity pathways.

This is a little scientific geekism, but what I'll tell you is that both of those are fundamental longevity pathways.

This is a little scientific geekism, but what I'll tell you is that both of those are fundamental longevity pathways.

And so what this then translated to when we did the algorithms of aging clock analysis of the immune cells is that we reduced the rate of aging of those immune cells by 47% over the course of three months.

And so what this then translated to when we did the algorithms of aging clock analysis of the immune cells is that we reduced the rate of aging of those immune cells by 47% over the course of three months.

And so what this then translated to when we did the algorithms of aging clock analysis of the immune cells is that we reduced the rate of aging of those immune cells by 47% over the course of three months.

reduced the rate of aging of the immune cells by 47%.

reduced the rate of aging of the immune cells by 47%.

reduced the rate of aging of the immune cells by 47%.

I mean, this had never been shown before. Now, let me be very honest. This was a pilot trial. It was a small number of subjects. It wasn't blinded. It wasn't placebo-controlled. So there's legitimate criticism that this doesn't fulfill all the gold standard criteria. But you're going to fix that. We are.

I mean, this had never been shown before. Now, let me be very honest. This was a pilot trial. It was a small number of subjects. It wasn't blinded. It wasn't placebo-controlled. So there's legitimate criticism that this doesn't fulfill all the gold standard criteria. But you're going to fix that. We are.

I mean, this had never been shown before. Now, let me be very honest. This was a pilot trial. It was a small number of subjects. It wasn't blinded. It wasn't placebo-controlled. So there's legitimate criticism that this doesn't fulfill all the gold standard criteria. But you're going to fix that. We are.